Emirates Mars Mission Characterization of Mars Atmosphere Dynamics and Processes

International audienceThe Emirates Mars Mission (EMM) - Hope Probe - was developed to understand Mars atmospheric circulation, dynamics, and processes through characterization of the Mars atmosphere layers and its interconnections enabled by a unique high-altitude (19,970 km periapse and 42,650 km apoapse) low inclination orbit that will offer an unprecedented local and seasonal time coverage over most of the planet. EMM has three scientific objectives to (A) characterize the state of the Martian lower atmosphere on global scales and its geographic, diurnal and seasonal variability, (B) correlate rates of thermal and photochemical atmospheric escape with conditions in the collisional Martian atmosphere, and (C) characterize the spatial structure and variability of key constituents in the Martian exosphere. The EMM data products include a variety of spectral and imaging data from three scientific instruments measuring Mars at visible, ultraviolet, and infrared wavelengths and contemporaneously and globally sampled on both diurnal and seasonal timescale. Here, we describe our strategies for addressing each objective with these data in addition to the complementary science data, tools, and physical models that will facilitate our understanding. The results will also fill a unique role by providing diagnostics of the physical processes driving atmospheric structure and dynamics, the connections between the lower and upper atmospheres, and the influences of these on atmospheric escape

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce deaths from intracranial bleeding after traumatic brain injury (TBI). To explore the mechanism of action of TXA in TBI, we examined the timing of its effect on death. Methods: The CRASH-3 trial randomised 9202 patients within 3 h of injury with a GCS score ≤ 12 or intracranial bleeding on CT scan and no significant extracranial bleeding to receive TXA or placebo. We conducted an exploratory analysis of the effects of TXA on all-cause mortality within 24 h of injury and within 28 days, excluding patients with a GCS score of 3 or bilateral unreactive pupils, stratified by severity and country income. We pool data from the CRASH-2 and CRASH-3 trials in a one-step fixed effects individual patient data meta-analysis. Results: There were 7637 patients for analysis after excluding patients with a GCS score of 3 or bilateral unreactive pupils. Of 1112 deaths, 23.3% were within 24 h of injury (early deaths). The risk of early death was reduced with TXA (112 (2.9%) TXA group vs 147 (3.9%) placebo group; risk ratio [RR] RR 0.74, 95% CI 0.58–0.94). There was no evidence of heterogeneity by severity (p = 0.64) or country income (p = 0.68). The risk of death beyond 24 h of injury was similar in the TXA and placebo groups (432 (11.5%) TXA group vs 421 (11.7%) placebo group; RR 0.98, 95% CI 0.69–1.12). The risk of death at 28 days was 14.0% in the TXA group versus 15.1% in the placebo group (544 vs 568 events; RR 0.93, 95% CI 0.83–1.03). When the CRASH-2 and CRASH-3 trial data were pooled, TXA reduced early death (RR 0.78, 95% CI 0.70–0.87) and death within 28 days (RR 0.88, 95% CI 0.82–0.94). Conclusions: Tranexamic acid reduces early deaths in non-moribund TBI patients regardless of TBI severity or country income. The effect of tranexamic acid in patients with isolated TBI is similar to that in polytrauma. Treatment is safe and even severely injured patients appear to benefit when treated soon after injury. Trial registration: ISRCTN15088122, registered on 19 July 2011; NCT01402882, registered on 26 July 2011